Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10329602" target="_blank" >RIV/00064165:_____/16:10329602 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/16:10329602

Výsledek na webu

<a href="http://dx.doi.org/10.1371/journal.pone.0166290" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0166290</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0166290" target="_blank" >10.1371/journal.pone.0166290</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease

Popis výsledku v původním jazyce

Background: Serum uric acid (UA) elevation is common in patients with cardiovascular, renal and metabolic diseases. However, no study to date has analysed the role of UA in Fabry disease (FD). Objectives: To evaluate the association between serum UA levels and mortality and morbidity in FD. Materials and Methods: We conducted a post-hoc analysis of a prospectively followed-up cohort of 124 patients with genetically proven FD. Serum UA levels were acquired at baseline; clinical events and mortality were assessed during regular visits every 6 to 12 months. The primary endpoint was a composite of multiple secondary outcomes: all-cause mortality, adverse cardiovascular events, progression of renal dysfunction and stroke or transient ischaemic attack (TIA). Predictive value was assessed using the Cox proportional hazards model and the Kaplan Meyer estimator.

Název v anglickém jazyce

Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease

Popis výsledku anglicky

Background: Serum uric acid (UA) elevation is common in patients with cardiovascular, renal and metabolic diseases. However, no study to date has analysed the role of UA in Fabry disease (FD). Objectives: To evaluate the association between serum UA levels and mortality and morbidity in FD. Materials and Methods: We conducted a post-hoc analysis of a prospectively followed-up cohort of 124 patients with genetically proven FD. Serum UA levels were acquired at baseline; clinical events and mortality were assessed during regular visits every 6 to 12 months. The primary endpoint was a composite of multiple secondary outcomes: all-cause mortality, adverse cardiovascular events, progression of renal dysfunction and stroke or transient ischaemic attack (TIA). Predictive value was assessed using the Cox proportional hazards model and the Kaplan Meyer estimator.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS ONE

ISSN

1932-6203

e-ISSN

—

Svazek periodika

11

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

—

Kód UT WoS článku

000387779200035

EID výsledku v databázi Scopus

2-s2.0-84994748470